Article Text

Download PDFPDF

816 NT-I7 and hIL-2/TCB2c combination promotes an immune-stimulatory tumor microenvironment that favors anti-tumor efficacy in combination with checkpoint inhibitors
  1. Minji Lee1,
  2. Sara Ferrando-Martinez2,
  3. Sun-Kyoung Im1,
  4. Seungtae Baek1,
  5. Mankyu Ji1,
  6. Miyoung Kim1,
  7. Eunju Lee1,
  8. Seung Taek Ji1,
  9. Daeun Kim3,
  10. Jun-Young Lee3 and
  11. Donghoon Choi1
  1. 1NeoImmuneTech, Co., Ltd., Pohang-si, Republic of Korea
  2. 2NeoImmuneTech, Inc., Rockville, MD, USA
  3. 3Selecxine Inc., Co., Ltd., Seoul, Republic of Korea
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background NT-I7 (efineptakin alfa; rhIL-7-hyFc) is a potent T-cell amplifier, with two IL-7 molecules fused to IgD/IgG4 elements. NT-I7 promotes extensive infiltration of CD8+ T cells to the tumor, concurrently increasing absolute numbers of PD-1+ CD8+ T cells in mice.1 2 Moreover, it expands central memory CD8+ T cells in tumors and tumor-draining lymph nodes. The hIL-2/TCB2 complex inhibits tumor growth by preferential activation of CD122 (IL-2Rβ)high CD8+ T cells and NK cells, without stimulating Treg. Both cytokines belong to the common gamma-chain cytokine family and induce antitumor effects. We investigated the synergistic antitumor efficacy and mechanisms of NT-I7 in combination with hIL-2/TCB2c, with or without PD-1 inhibitor.

Methods MC38 and/or CT26 tumor-bearing mice were administered a single dose of 10 mg/kg NT-I7 intramuscularly (IM) and 0.9 mg/kg hIL-2/TCB2c intravenously (IV). Anti-PD-1 monoclonal antibody was administered intraperitoneally three times with three-day intervals at a dose of 5 mg/kg. Tumor volume was measured to assess efficacy. To compare the composition of immune cells between each monotherapy and the combination therapy, we analyzed tumor and tumor-draining lymph nodes (TDLN) by flow cytometry.

Results Our data demonstrated that the combination of NT-I7 and hIL-2/TCB2c synergistically inhibits tumor growth and generates an immune-stimulatory tumor microenvironment (TME). This TME was characterized by an increased infiltration of tumor-specific CD8+ T cells, and a decreased frequency of CD11b+ MDSCs and CD39high TIM-3+ Treg cells, known to be highly immunosuppressive. Most importantly, NT-I7 increased infiltration of CD62L+Ly108+ early progenitor population of exhausted CD8+ T cells (TPEX), which may retain long-term proliferation capacity and replenish functional effector CD8+ T cells. IL-2/TCB2c treatment induces differentiation of CD62L+Ly108+ TPEX rapidly into CD101+ terminally differentiated subsets. Remarkably, our study demonstrated that NT-I7 significantly enhances the proliferation rate of CD8+ TPEX as well as memory T cells in the tumor-draining lymph nodes (TDLNs), positively correlated with the abundance of TPEX within the tumor. These findings strongly suggest that the expansion of TPEX, following NT-I7 administration, originates from the TDLNs. Moreover, the addition of PD-1 blockade further enhances the therapeutic efficacy of NT-I7 plus hIL-2/TCB2c, leading to complete regression of tumors.

Conclusions NT-I7 dramatically and preferentially increased TPEX and less exhausted T cells, while hIL-2/TCB2c induced the differentiation of these cells. These findings highlight that NT-I7 in combination with other immunotherapies, such as IL-2 and/or CPI, can enhance the anti-tumor efficacy.


  1. Kim JH Kim, YM Kim, D Choi, SB Jo, HW Park, SW Hong, et al. Hybrid Fc-fused interleukin-7 induces an inflamed tumor microenvironment and improves the efficacy of cancer immunotherapy. Clinical & Translational Immunology 2020;9(9):1–16.

  2. Lee JY, Lee E, Hong SW, Kim D, Eunju O, Sprent J, Im SH, Lee YJ, Surh CD. TCB2, a new anti-human interleukin-2 antibody, facilitates heterodimeric IL-2 receptor signaling and improves anti-tumor immunity. Oncoimmunology. 2019 Nov 4;9(1):1681869.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.